Deerfield Management ARDX Position
Exited3-Fund ConvergenceDeerfield Management exited their position in Ardelyx Inc. (ARDX) in Q4 2024, after holding the stock for 2 quarters.
The position was first reported in Q3 2024 and has been tracked across 2 quarterly 13F filings.
ARDX is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 3 readout for Tenapanor 50 MG in 46 days (Jun 1, 2026), making the timing of Deerfield's position particularly relevant.
About Ardelyx Inc.
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Full company profile →Short Interest
10.0%
5.0 days to cover
Deerfield Management ARDX Position History
Frequently Asked Questions
Does Deerfield Management own ARDX?
No. Deerfield Management exited their position in Ardelyx Inc. (ARDX) in Q4 2024. They previously held the stock for 2 quarters.
How many hedge funds own ARDX?
3 specialist biotech hedge funds currently hold ARDX, including Eventide Asset Management, Redmile Group, Rock Springs Capital. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deerfield Management first buy ARDX?
Deerfield Management's position in ARDX was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deerfield Management's ARDX position increasing or decreasing?
Deerfield Management completely exited their ARDX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ARDXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deerfield ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →